BioVie Inc.-2026年季度报告

(Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the quarterly period ended: December 31, 2025 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period from ____________to _____________Commission File Number:001-39015BIOVIE INC.(Exact name of registrant as specified in its charter) 680 W Nye Lane Suite 204Carson City, NV 89703 Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Actduring the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller Large Accelerated FilerNon-Accelerated Filer If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). TABLE OF CONTENTS PART I – FINANCIAL INFORMATION Item 1.Unaudited Financial Statements Condensed Statements of Cash Flows - for the six months ended December 31, 2025 and 2024Notes to Unaudited Condensed Financial Statements PART II – OTHER INFORMATION Item 1.Legal Proceedings27Item 1A.Risk Factors27 Table of Contents BIOVIE INC. FORWARD-LOOKING STATEMENTS This report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, asamended (the “Exchange Act”), and Section 27A of the Securities Act of 1933, as amended (the “Securities Act”). Any statementscontained in this report that are not statements of historical fact may be forward-looking statements. When we use the words “intends,”“estimates,” “predicts,” “potential,” “continues,” “anticipates,” “plans,” “expects,” “believes,” “should,” “could,” “may,” “will” or thenegative of these terms or other comparable terminology, we are identifying forward-looking statements. Forward-looking statementsinvolve risks and uncertainties, which may cause our actual results, performance or achievements to be materially different from those Except as may be required by applicable law, we do not undertake or intend to update or revise our forward-looking statements, andwe assume no obligation to update any forward-looking statements contained in this report as a result of new information or futureevents or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressedor implied in such forward-looking statements. You should carefully review and consider the various disclosures we make in this When used in this report, the terms “BioVie”, “Company”, “we”, “our”, and “us” refer to BioVie Inc. BioVie Inc.Notes to Condensed Financial Statements 1.Background Information BioVie Inc. (the “Company” or “we” or “our”) is a clinical-stage company developing innovative drug therapies for the treatment ofneurological and neurodegenerative disorders and advanced liver disease. Neurodegenerative Disease Programs The Company acquired the biopharmaceutical assets of NeurMedix, Inc. (“NeurMedix”) a privately held clinical-stage pharmaceuticalcompany and a related party in June 2021.The acquired assets included NE3107 (or “bezisterim”). Bezisterim, the approved genericname for NE3107 is an investigational, novel, orally administered small molecule that is thought to inhibit inflammation-driven insulinresistance and major pathological inflammatory cascades with a novel mechanism of action. There is emerging scientific consensusthat both inflammation and insulin resistance may play fundamental roles in the development of Alzheimer’s disease (“AD”) andParkinson’s disease (“PD”), and bezisterim could, if approved by the U.S. Food and Drug Administration (“FDA”), represent an In neurodegenerative disease, the Company’s drug candidate bezisterim is an orally bioavailable, Blood Brain Barrier (“BBB”)-permeable, insulin-sensitizer that is also anti-inflammatory. In addition, it is not immunosuppressive and has a low risk of drug-druginteraction. Bezisterim inhibits activation of inflammatory action extracellular single regulated kinase (“E